U.S. Markets close in 4 hrs 32 mins

Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2%

Zacks Equity Research

Spectrum Pharmaceuticals, Inc. SPPI was a big mover last session, as the company saw its shares jump a little above 22% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $7.28 to $8.25 in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved lower over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Spectrum currently carries a Zacks Rank #3 (Hold).

Spectrum Pharmaceuticals, Inc. Price


Spectrum Pharmaceuticals, Inc. Price | Spectrum Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical - Drugs industry is Aerie Pharmaceuticals, Inc. AERI, which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is SPPI going up? Or down? Predict to see what others think:  Up or Down

5 Trades Could Profit "Big-League" from Trump Policies                                                                                                                       

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Spectrum Pharmaceuticals, Inc. (SPPI) : Free Stock Analysis Report
Aerie Pharmaceuticals, Inc. (AERI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research